Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders

Vyanka Redenbaugh; Mayra Montalvo; Elia Sechi; Marina Buciuc; James P. Fryer; Andrew McKeon; Vanda A. Lennon; John R. Mills; Brian G. Weinshenker; Dean M. Wingerchuk; John J. Chen; M. Tariq Bhatti; A. Sebastian Lopez Chiriboga; Sean J. Pittock; Eoin P. Flanagan

doi:10.1177/20552173211052656

Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders

Vyanka Redenbaugh, Mayra Montalvo, Elia Sechi, Marina Buciuc, James P. Fryer, Andrew McKeon, Vanda A. Lennon, John R. Mills, Brian G. Weinshenker, Dean M. Wingerchuk, John J. Chen, M. Tariq Bhatti, A. Sebastian Lopez Chiriboga, Sean J. Pittock, Eoin P. Flanagan

Research output: Contribution to journal › Article › peer-review

Abstract

Objective: Determine the utility of aquaporin 4 IgG (AQP4-IgG) testing (live cell-based assay) for Neuromyelitis Optica Spectrum Disorders (NMOSD). Methods: We included Mayo Clinic patients (1/1/2018-12/31/2019) tested for serum AQP4-IgG by live cell-based flow-cytometric assay. Medical records were reviewed to assess if patients fulfilled 2015 NMOSD criteria. Results: Of 1371 patients tested, 41 were positive (3%) and all fulfilled NMOSD criteria with AQP4-IgG (specificity = 100%). Only 10/1330 testing negative met NMOSD criteria without AQP4-IgG (sensitivity = 80%) and seven of these 10 were MOG-IgG positive. Conclusions: AQP4-IgG by live cell-based assay was highly specific and without false positives in a high throughput setting.

Original language	English (US)
Journal	Multiple Sclerosis Journal - Experimental, Translational and Clinical
Volume	7
Issue number	4
DOIs	https://doi.org/10.1177/20552173211052656
State	Published - Oct 2021

ASJC Scopus subject areas

Clinical Neurology
Cellular and Molecular Neuroscience

Access to Document

10.1177/20552173211052656

Cite this

Redenbaugh, V., Montalvo, M., Sechi, E., Buciuc, M., Fryer, J. P., McKeon, A., Lennon, V. A., Mills, J. R., Weinshenker, B. G., Wingerchuk, D. M., Chen, J. J., Tariq Bhatti, M., Lopez Chiriboga, A. S., Pittock, S. J., & Flanagan, E. P. (2021). Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 7(4). https://doi.org/10.1177/20552173211052656

Redenbaugh, V, Montalvo, M, Sechi, E, Buciuc, M, Fryer, JP, McKeon, A , Lennon, VA, Mills, JR, Weinshenker, BG, Wingerchuk, DM , Chen, JJ, Tariq Bhatti, M, Lopez Chiriboga, AS, Pittock, SJ & Flanagan, EP 2021, 'Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders', Multiple Sclerosis Journal - Experimental, Translational and Clinical, vol. 7, no. 4. https://doi.org/10.1177/20552173211052656

@article{519aec496aae4206ad47198ae3c3ede3,

title = "Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders",

abstract = "Objective: Determine the utility of aquaporin 4 IgG (AQP4-IgG) testing (live cell-based assay) for Neuromyelitis Optica Spectrum Disorders (NMOSD). Methods: We included Mayo Clinic patients (1/1/2018-12/31/2019) tested for serum AQP4-IgG by live cell-based flow-cytometric assay. Medical records were reviewed to assess if patients fulfilled 2015 NMOSD criteria. Results: Of 1371 patients tested, 41 were positive (3%) and all fulfilled NMOSD criteria with AQP4-IgG (specificity = 100%). Only 10/1330 testing negative met NMOSD criteria without AQP4-IgG (sensitivity = 80%) and seven of these 10 were MOG-IgG positive. Conclusions: AQP4-IgG by live cell-based assay was highly specific and without false positives in a high throughput setting.",

author = "Vyanka Redenbaugh and Mayra Montalvo and Elia Sechi and Marina Buciuc and Fryer, {James P.} and Andrew McKeon and Lennon, {Vanda A.} and Mills, {John R.} and Weinshenker, {Brian G.} and Wingerchuk, {Dean M.} and Chen, {John J.} and {Tariq Bhatti}, M. and {Lopez Chiriboga}, {A. Sebastian} and Pittock, {Sean J.} and Flanagan, {Eoin P.}",

note = "Publisher Copyright: {\textcopyright} The Author(s), 2021.",

year = "2021",

month = oct,

doi = "10.1177/20552173211052656",

language = "English (US)",

volume = "7",

journal = "Multiple Sclerosis Journal - Experimental, Translational and Clinical",

issn = "2055-2173",

publisher = "SAGE Publications Inc.",

number = "4",

}

TY - JOUR

T1 - Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders

AU - Redenbaugh, Vyanka

AU - Montalvo, Mayra

AU - Sechi, Elia

AU - Buciuc, Marina

AU - Fryer, James P.

AU - McKeon, Andrew

AU - Lennon, Vanda A.

AU - Mills, John R.

AU - Weinshenker, Brian G.

AU - Wingerchuk, Dean M.

AU - Chen, John J.

AU - Tariq Bhatti, M.

AU - Lopez Chiriboga, A. Sebastian

AU - Pittock, Sean J.

AU - Flanagan, Eoin P.

PY - 2021/10

Y1 - 2021/10

N2 - Objective: Determine the utility of aquaporin 4 IgG (AQP4-IgG) testing (live cell-based assay) for Neuromyelitis Optica Spectrum Disorders (NMOSD). Methods: We included Mayo Clinic patients (1/1/2018-12/31/2019) tested for serum AQP4-IgG by live cell-based flow-cytometric assay. Medical records were reviewed to assess if patients fulfilled 2015 NMOSD criteria. Results: Of 1371 patients tested, 41 were positive (3%) and all fulfilled NMOSD criteria with AQP4-IgG (specificity = 100%). Only 10/1330 testing negative met NMOSD criteria without AQP4-IgG (sensitivity = 80%) and seven of these 10 were MOG-IgG positive. Conclusions: AQP4-IgG by live cell-based assay was highly specific and without false positives in a high throughput setting.

AB - Objective: Determine the utility of aquaporin 4 IgG (AQP4-IgG) testing (live cell-based assay) for Neuromyelitis Optica Spectrum Disorders (NMOSD). Methods: We included Mayo Clinic patients (1/1/2018-12/31/2019) tested for serum AQP4-IgG by live cell-based flow-cytometric assay. Medical records were reviewed to assess if patients fulfilled 2015 NMOSD criteria. Results: Of 1371 patients tested, 41 were positive (3%) and all fulfilled NMOSD criteria with AQP4-IgG (specificity = 100%). Only 10/1330 testing negative met NMOSD criteria without AQP4-IgG (sensitivity = 80%) and seven of these 10 were MOG-IgG positive. Conclusions: AQP4-IgG by live cell-based assay was highly specific and without false positives in a high throughput setting.

UR - http://www.scopus.com/inward/record.url?scp=85120359380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85120359380&partnerID=8YFLogxK

U2 - 10.1177/20552173211052656

DO - 10.1177/20552173211052656

M3 - Article

AN - SCOPUS:85120359380

SN - 2055-2173

VL - 7

JO - Multiple Sclerosis Journal - Experimental, Translational and Clinical

JF - Multiple Sclerosis Journal - Experimental, Translational and Clinical

IS - 4

ER -

Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this